Thrombocytopenia Complicating Transcatheter Aortic Valve Implantation: Differences Between Two New-Generation Devices.
Inflammatory cytokines
Phagocytic monocytes
Platelet cell death
TAVI
Thrombocytopenia
Journal
Journal of cardiovascular translational research
ISSN: 1937-5395
Titre abrégé: J Cardiovasc Transl Res
Pays: United States
ID NLM: 101468585
Informations de publication
Date de publication:
12 2021
12 2021
Historique:
received:
01
01
2021
accepted:
25
02
2021
pubmed:
16
3
2021
medline:
8
2
2022
entrez:
15
3
2021
Statut:
ppublish
Résumé
Thrombocytopenia after TAVI is common and clinically detrimental. Retrospectively, we observed Portico recipients had a more profound platelet drop than Evolut recipients. We thus investigated periprocedural platelet damage and/orpro-inflammatory state in 64 TAVI recipients at baseline and after implantation. Platelet damage was assessed by annexin V staining and monocyte-phagocytic phenotype was assessed according to CD14/CD36 expression. Serum cytokines were measured in 20 patients. The formaldehyde-based storage solution altered platelets. When, before being loaded onto the delivery system, Portico underwent one additional flushing to those recommended, the receiving patients showed thrombocytopenia, platelet damage, and CD36-monocyte count were mitigated. A general increase in IL-6 was recorded in overall TAVI recipients, but a high serum level of IL-8, a potent thrombocytopenia inducer, was measured in Portico recipients only, including those with extra-rinsed valve. Our study suggests a platelet-injury effect by storage-solution and generates the hypothesis of a role for the biomaterial in stimulating innate-immunity. Larger prospective studies are needed. Graphical Abstract.
Identifiants
pubmed: 33721196
doi: 10.1007/s12265-021-10117-9
pii: 10.1007/s12265-021-10117-9
pmc: PMC8651580
doi:
Substances chimiques
Biomarkers
0
Cytokines
0
Types de publication
Comparative Study
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1104-1113Informations de copyright
© 2021. The Author(s).
Références
Transfus Apher Sci. 2020 Dec;59(6):102883
pubmed: 32807650
Circ Cardiovasc Interv. 2012 Apr;5(2):296-304
pubmed: 22511738
Minerva Cardioangiol. 2019 Dec;67(6):443-449
pubmed: 31670491
Catheter Cardiovasc Interv. 2019 Nov 15;94(6):812-817
pubmed: 31062487
Circ J. 2020 May 25;84(6):1020-1027
pubmed: 32336739
J Cardiovasc Med (Hagerstown). 2017 Feb;18(2):96-102
pubmed: 27898500
Adv Med Sci. 2017 Sep;62(2):378-382
pubmed: 28550795
Tex Heart Inst J. 2012;39(1):86-91
pubmed: 22412237
Int J Cardiol. 2021 Jan 1;322:86-94
pubmed: 32814109
PLoS One. 2015 Nov 23;10(11):e0143089
pubmed: 26599610
Arterioscler Thromb Vasc Biol. 2016 Feb;36(2):211-2
pubmed: 26819460
Eur Heart J. 2012 Jun;33(12):1459-68
pubmed: 22285582
Am J Cardiol. 2020 Aug 15;129:60-70
pubmed: 32565091
J Exp Med. 1995 May 1;181(5):1857-62
pubmed: 7536797
Mediators Inflamm. 2017;2017:9605894
pubmed: 29170605
Eur Heart J. 2014 Oct 7;35(38):2663-71
pubmed: 24598983
Int J Cardiol. 2016 Nov 15;223:95-97
pubmed: 27532241
Angiology. 2021 Mar;72(3):290-294
pubmed: 32873055
Thromb Res. 2017 Aug;156:39-44
pubmed: 28582640
J Thromb Thrombolysis. 2019 Feb;47(2):174-178
pubmed: 30484011
Clin Lab Haematol. 2005 Apr;27(2):91-7
pubmed: 15784123
Immunity. 2007 Dec;27(6):952-64
pubmed: 18093541
Mediators Inflamm. 1994;3(4):281-5
pubmed: 18472953
Minerva Cardioangiol. 2018 Dec;66(6):747-761
pubmed: 29687702
Minerva Cardiol Angiol. 2021 Jun;69(3):358-369
pubmed: 32989964
Catheter Cardiovasc Interv. 2021 Jul 1;98(1):E139-E144
pubmed: 33058433
Blood. 2005 Oct 1;106(7):2417-23
pubmed: 15961512
FEBS Lett. 1992 Jul 27;307(1):97-101
pubmed: 1639201
Sci Rep. 2016 Aug 26;6:32188
pubmed: 27561337
J Cardiovasc Med (Hagerstown). 2020 Apr;21(4):318-324
pubmed: 32108127